# Daniel S.W. Tan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/daniel-s-w-tan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,697 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 57 |
| i10-index | 138 |
| Last Known Institution | National Cancer Centre Singapore |
| OpenAlex ID | https://openalex.org/A5063823247 |
| ORCID iD | 0000-0002-6514-6786 |
| Works | 508 |

## Researcher papers

Showing 12 of 15.

- [Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/ceritinib-in-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates](https://scholariq.org/papers/bystander-cd8-t-cells-are-abundant-and-phenotypically-distinct-in-human-tumour/)
- [First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study](https://scholariq.org/papers/first-line-ceritinib-versus-platinum-based-chemotherapy-in-advanced-alk/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-altered-thyroid-cancers/)
- [Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations](https://scholariq.org/papers/targeted-therapies-for-lung-cancer-patients-with-oncogenic-driver-molecular/)
- [Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer](https://scholariq.org/papers/liquid-biopsy-for-advanced-nsclc-a-consensus-statement-from-the-international/)
- [A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer](https://scholariq.org/papers/a-common-bim-deletion-polymorphism-mediates-intrinsic-resistance-and-inferior/)
- [Genomic landscape of lung adenocarcinoma in East Asians](https://scholariq.org/papers/genomic-landscape-of-lung-adenocarcinoma-in-east-asians/)
- [Non-small-cell lung cancer](https://scholariq.org/papers/non-small-cell-lung-cancer-2/)
- [Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial](https://scholariq.org/papers/activity-and-safety-of-ceritinib-in-patients-with-alk-rearranged-non-small-cell/)
- [Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study](https://scholariq.org/papers/pralsetinib-for-ret-fusion-positive-non-small-cell-lung-cancer-arrow-a-multi/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Researcher university

- [National Cancer Centre Singapore](https://scholariq.org/institutions/national-cancer-centre-singapore/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.